Number of Adverse events;Positive result of acute SARS-CoV-2 infection;Positive result of acute SARS-CoV-2 infection;Positive result of Severe COVID-19;Positive result of Severe COVID-19

Number of Adverse events;Positive result of acute SARS-CoV-2 infection;Positive result of acute SARS-CoV-2 infection;Positive result of Severe COVID-19;Positive result of Severe COVID-19

To assess the relative risk of severe COVID-19 after the Month 6 dose among those who received mRNA-1273 at Month 6 vs. those who received mRNA-1273.222 at Month 6, counting endpoints least 14 days after the Month 6 dose until end of follow up.;to assess the relative risk of severe COVID-19 in Group 1 (PLWH who are SARS- CoV-2 negative at baseline) who receive a 2-dose mRNA- 1273 vaccine regimen vs. in Group 2 (PLWH who are SARS-CoV-2 positive at baseline) who receive a 1-dose;To assess the relative risk of symptomatic COVID-19 after the Month 6 dose among those who received mRNA-1273 at Month 6 vs. those who received mRNA-1273.222 at Month 6, counting endpoints least 14 days after the Month 6 dose until end of follow up.;To assess the relative risk of symptomatic COVID-19 in Group 1 (PLWH who are SARS-CoV-2 negative at baseline) who receive a 2-dose mRNA-1273 vaccine regimen vs. in Group 2 (PLWH who are SARS-CoV-2 positive at baseline) who receive a 1-dose regimen;To assess the safety and tolerability of mRNA-1273 and mRNA-1273.222 in adults who are at risk of severe COVID 6 and post-Month 6 stages.

To assess the relative risk of severe COVID-19 after the Month 6 dose among those who received mRNA-1273 at Month 6 vs. those who received mRNA-1273.222 at Month 6, counting endpoints least 14 days after the Month 6 dose until end of follow up.;to assess the relative risk of severe COVID-19 in Group 1 (PLWH who are SARS- CoV-2 negative at baseline) who receive a 2-dose mRNA- 1273 vaccine regimen vs. in Group 2 (PLWH who are SARS-CoV-2 positive at baseline) who receive a 1-dose;To assess the relative risk of symptomatic COVID-19 after the Month 6 dose among those who received mRNA-1273 at Month 6 vs. those who received mRNA-1273.222 at Month 6, counting endpoints least 14 days after the Month 6 dose until end of follow up.;To assess the relative risk of symptomatic COVID-19 in Group 1 (PLWH who are SARS-CoV-2 negative at baseline) who receive a 2-dose mRNA-1273 vaccine regimen vs. in Group 2 (PLWH who are SARS-CoV-2 positive at baseline) who receive a 1-dose regimen;To assess the safety and tolerability of mRNA-1273 and mRNA-1273.222 in adults who are at risk of severe COVID 6 and post-Month 6 stages.

Adverse events of special interest (AESIs) collected for all participants;Number of participants (baseline persons living with HIV [PLWH] and SARS-CoV-2 negative) with COVID-19;Number of participants (baseline PLWH and SARS-CoV-2 negative) with severe COVID-19;Serious adverse events (SAEs) collected for all participants;Solicited Adverse events for a subset of participants;Unsolicited adverse events collected for a subset of participants

Adverse events of special interest (AESIs) collected for all participants;Number of participants (baseline persons living with HIV [PLWH] and SARS-CoV-2 negative) with COVID-19;Number of participants (baseline PLWH and SARS-CoV-2 negative) with severe COVID-19;Serious adverse events (SAEs) collected for all participants;Solicited Adverse events for a subset of participants;Unsolicited adverse events collected for a subset of participants